Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | XDH | P47989 | 3/20 | 0.59 |
| ▸ | F2 | P00734 | 1/20 | 0.58 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.53 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.49 |
| ▸ | USP7 | Q93009 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3961463 | 0.88 | MAPK14 (0.58) | KMT2AKDM4EMEN1XDHF2 | |
| SCHEMBL30120645 | 0.84 | KMT2A (0.71) | KMT2AKDM4EMEN1XDHF2 | |
| SCHEMBL544885 | 0.84 | KMT2A (0.71) | KMT2AKDM4EMEN1XDHF2 | |
| SCHEMBL1456317 | 0.83 | KMT2A (0.71) | KMT2AKDM4EMEN1XDHPTGS2 | |
| SCHEMBL3871978 | 0.82 | KMT2A (0.62) | KMT2AKDM4EMEN1XDHNPBWR1 | |
| SCHEMBL17877705 | 0.81 | KMT2A (0.61) | KMT2AKDM4EMEN1XDHF2 | |
| SCHEMBL3876365 | 0.81 | KMT2A (0.73) | KMT2AKDM4EMEN1XDHPTGS2 | |
| SCHEMBL1143771 | 0.80 | KMT2A (0.71) | KMT2AKDM4EMEN1XDHPTGS1 | |
| SCHEMBL4700651 | 0.80 | KMT2A (0.71) | KMT2AKDM4EMEN1XDHPTGS1 | |
| SCHEMBL3871259 | 0.80 | KMT2A (1.00) | KMT2AKDM4EMEN1XDHPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230140216-A1 | COMBINATION THERAPY FOR TREATING MPS1 | GAIN THERAPEUTICS SA (CH) | 2023-05-04 | — | — | US | disclosed |
| US-20230140216-A1 | COMBINATION THERAPY FOR TREATING MPS1 | GAIN THERAPEUTICS SA (CH) | 2023-05-04 | — | — | US | disclosed |
| US-20230140216-A1 | COMBINATION THERAPY FOR TREATING MPS1 | GAIN THERAPEUTICS SA (CH) | 2023-05-04 | — | — | US | disclosed |
| EP-4100015-A1 | COMBINATION THERAPY FOR TREATING MPS1 | Gain Therapeutics SA (CH) | 2022-12-14 | — | — | EP | disclosed |
| CN-115397423-A | Combination therapy for the treatment of MPS1 | 增益治疗股份有限公司 | 2022-11-25 | — | — | CN | disclosed |
| WO-2021156774-A1 | COMBINATION THERAPY FOR TREATING MPS1 | GAIN THERAPEUTICS SA (CH) | 2021-08-12 | — | — | WO | disclosed |
| WO-2021156774-A1 | COMBINATION THERAPY FOR TREATING MPS1 | GAIN THERAPEUTICS SA (CH) | 2021-08-12 | — | — | WO | disclosed |
| US-20100093821-A1 | 3-Amino-pyrazole-4-carboxamide derivatives useful as inhibitors of protein kinases | HOLZER PHILIPP | 2010-04-15 | — | — | US | disclosed |
| EP-2079702-A1 | 3-AMINO-PYRAZOLE-4-CARBOXAMIDE DERIVATIVES USEFUL AS INHIBITORS OF PROTEIN KINASES | Novartis AG (CH) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008052974-A1 | 3-AMINO-PYRAZOLE-4-CARBOXAMIDE DERIVATIVES USEFUL AS INHIBITORS OF PROTEIN KINASES | NOVARTIS AG (CH) | 2008-05-08 | — | — | WO | disclosed |
| US-20060167020-A1 | Pyrazolopyrimidines as kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-07-27 | — | — | US | disclosed |
| EP-1551841-A1 | PYRAZOLOPYRIMIDINES AS KINASE INHIBITORS | SmithKline Beecham Corporation (US) | 2005-07-13 | — | — | EP | disclosed |
| EP-1523314-A2 | PYRAZOLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS | SmithKline Beecham Corporation (US) | 2005-04-20 | — | — | EP | disclosed |
| WO-2004009602-A1 | PYRAZOLOPYRIMIDINES AS KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-01-29 | — | — | WO | disclosed |
| WO-2004009602-A1 | PYRAZOLOPYRIMIDINES AS KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-01-29 | — | — | WO | disclosed |
| WO-2004009597-A2 | PYRAZOLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-01-29 | — | — | WO | disclosed |
| US-4920119-A | XANTHINE OXIDASE INHIBITORS; CONTROL OR PREVENTION OF GOUT OR ISCHEMIA | HOFFMANN-LA ROCHE INC. (US) | 1990-04-24 | — | — | US | disclosed |
| EP-0274654-A2 | 1,2,3-Triazin-4(3H)-one derivatives, process for their preparation and medicaments containing them | F. HOFFMANN-LA ROCHE AG (CH) | 1988-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230140216-A1 | COMBINATION THERAPY FOR TREATING MPS1 | IDUA, MAN2B1, GBA1 | KMT2A 3761/4885KDM4E 3566/4885MEN1 1434/4885 |
| US-20060167020-A1 | Pyrazolopyrimidines as kinase inhibitors | MAP3K12, MAP3K5, MAP3K2 | KMT2A 1420/4885KDM4E 1432/4885MEN1 3379/4885 |
| US-20100093821-A1 | 3-Amino-pyrazole-4-carboxamide derivatives useful as inhibitors of protein kinases | MAP4K2, MAP4K3, MAP4K1 | KMT2A 875/4885KDM4E 907/4885MEN1 3441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.